Clinical Trials
16 trialsNCT06645886 2026-03-25
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
Kumquat Biosciences Inc.
Phase 1 Active not recruiting
NCT04580121 2024-06-03
A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
Hoffmann-La Roche
Phase 1 Completed
NCT02081378 2024-03-18
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
Novartis
Phase 1 Completed
NCT00306202 2021-02-26
Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia
Bristol-Myers Squibb
Phase 1 Completed
NCT02011945 2020-03-18
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Bristol-Myers Squibb
Phase 1 Completed
NCT00560352 2017-03-13
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
Bristol-Myers Squibb
Phase 1 Terminated
NCT00560391 2016-08-04
Dasatinib in Combination With Revlimid (and Dexamethasone)
Bristol-Myers Squibb
Phase 1 Completed
NCT00324077 2016-02-17
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT00452673 2015-03-24
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT00500006 2015-01-30
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00872976 2013-07-22
Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT00978731 2011-04-28
Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study
Bristol-Myers Squibb
Phase 1 Completed
NCT00099606 2011-04-19
Phase I (PH I) Mad Refractory Solid Tumor Study
Bristol-Myers Squibb
Phase 1 Completed
NCT00103701 2011-04-14
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
Bristol-Myers Squibb
Phase 1 Completed
NCT00162214 2011-04-14
Study of Dasatinib in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Terminated
NCT00339144 2010-12-15
Study of Dasatinib (BMS-354825) in Patients With Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed